Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC (NCT03410615)
Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)
🩺 Plain-English Summary (8th-Grade Level)
Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards
Who can join: Review the eligibility criteria below.
Location: Cliniques Universitaires Saint-Luc — Brussels
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Cliniques Universitaires Saint-Luc — Brussels,
- University Hospital of Antwerp — Edegem,
- University Hospital of Gent — Ghent,
- University Hospital Leuven — Leuven,
- Clinique St. Elizabeth — Namur,
- AZ Sint Augustinus — Wilrijk,
- Cross Cancer Institute — Edmonton, Alberta
- CancerCare Manitoba — Winnipeg, Manitoba
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Health Sciences North — Greater Sudbury, Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario
- London Regional Cancer Program — London, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- University Health Network — Toronto, Ontario
- The Jewish General Hospital — Montreal, Quebec
- The Research Institute of the McGill University — Montreal, Quebec
- CIUSSS de l'Estrie - Centre hospitalier — Sherbrooke, Quebec
- Allan Blair Cancer Centre — Regina, Saskatchewan
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan,
- Complejo Hospitalario de Navarra — Pamplona, Navarre
- University Hospital Vall dHebron — Barcelona,
- Hospital Duran i Reynals — Barcelona,
- University Hospital Ramon y Cajal — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oropharyngeal Squamous Cell Carcinoma
- Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma — New York, New York
- Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma — Cincinnati, Ohio
- Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma — Gainesville, Florida
- Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma — St Louis, Missouri
- Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC — Rochester, Minnesota
Explore by condition: All Oropharyngeal Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.